Looking for a new broker?
Aravive, Inc. stock is up 6.31% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November.
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the signaling pathway.
